Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Genmab
Novartis
Regeneron Pharmaceuticals
University of Michigan Rogel Cancer Center
Celgene
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Sana Biotechnology
Celgene
Gilead Sciences
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
City of Hope Medical Center
City of Hope Medical Center
Synthekine
Malaghan Institute of Medical Research